A Comprehensive Study of Repetitive Transcranial Magnetic Stimulation in Parkinson's Disease
Table 1
Profiles of 12 PD patients.
Case
Sex
Age (years)
Disease duration (years)
Modified Hoehn and Yah Stage (1)
Schwab and England ADLScale (1)
L-DOPA (2) (mg)
D2 agonists (3)
Amantadine (mg)
Droxydopa (mg)
Trihexi-phenidyl (mg)
Other drugs
Drugs
Dosage (mg)
1
Man
57
1
3
80%
300*
CB
1
0
0
0
Maprotiline, flunitrazepam
2
Man
67
13
3
60%
300
BC
7.5
150
300
4
3
Woman
70
8
2.5
80%
300
none
—
0
300
0
4
Man
66
6
2.5
80%
300
PG
0.3
100
600
4
5
Man
64
9
2.5
80%
400
BC
15
0
200
4
6
Woman
76
14
3
70%
500
BC
10
50
0
0
Imipramine, flurazepam
7
Man
73
11
4
50%
400
PG
1
0
900
0
Imipramine, clonazepam
8
Woman
69
2
3
80%
300
PG
0.1
0
600
0
9
Woman
75
12
2.5
60%
300
PG
0.75
100
0
0
10
Man
78
12
4
30%
400
PG
0.75
50
600
0
Mitodrine
11
Man
67
4
2.5
90%
450
PG
0.75
0
0
6
12
Woman
68
10
2
80%
450
BC
15
0
0
6
(1) Under the drug-off state at before sham rTMS. (2) Levodopa-carbidopa combination. *Levodopa-benserazide combination. (3) CB: cabergolin, BC: bromocriptine, PG: pergolide.
